Tenet Healthcare Stock Is Up 56% in a Year — But Is the Best Part Already Over?

A certain type of stock doesn’t receive much attention until it has accomplished something noteworthy. Among them is Tenet Healthcare. This Dallas-based hospital operator was quietly developing one of the more interesting healthcare stories while investors were chasing AI names and semiconductor plays for the majority of the previous year. Now that the share price has surpassed $280, everyone seems to be paying attention at once.

It’s hard to ignore the numbers. Tenet Healthcare’s stock has increased by over 270% over the last five years and by about 56% over the last year. That kind of performance begs the obvious question of what precisely changed for a business that operates in a sector characterized by labor pressures, payer complexity, and razor-thin margins.

Execution is the short answer. The story was fairly clear from the Q2 2026 results. At $5.63 billion, net operating revenue increased by almost 7% from the previous year. At $6.12, adjusted diluted earnings per share increased by more than 52%. Ambulatory revenue, which is based on outpatient procedures and surgical centers, increased by more than 9%. However, the top-line growth was not the most striking detail. The hospital’s adjusted EBITDA margin increased from 15.6% to 18%. That kind of margin improvement doesn’t happen by accident in hospital operations, where labor costs are stubborn and patient volume can fluctuate.

Wall Street may only now be catching up to a company that has been subtly changing for a number of years. Tenet has been directing its ambulatory segment toward higher-acuity procedures, which produce better margins and stronger reimbursements. In the meantime, the hospital side has tightened operations in ways that are beginning to appear in published data. It’s not exactly a turnaround story. It seems more like a discipline that has been gradually developing and has now reached a discernible threshold.

However, it’s important to take a moment to consider that the valuation debate is still genuinely unresolved. Currently trading at a P/E of 10.8x, the stock appears cheap when compared to the larger healthcare industry, which is closer to 25x. Using Tenet’s most recent twelve-month free cash flow data, a discounted cash flow analysis indicates an intrinsic value of about $554 per share, suggesting the stock is still substantially undervalued even after its long run. There is still significant upside on that reading.

However, that is not how everyone sees it. Citing slower anticipated revenue growth, thinner future margins, and a valuation that may already represent the most optimistic version of the company’s near-term trajectory, the more pessimistic camp suggests a fair value closer to $250—below where the stock currently trades. It is reasonable to wonder how much good news has already been factored in after a 61% gain in just ninety days.

Tenet appears to be at an intriguing turning point for healthcare investors in general as this develops. The question of whether hospital-centered businesses could withstand the transition to outpatient care used to be the topic of discussion. In essence, Tenet’s reaction has been to take responsibility for both aspects of that situation. It’s still unclear if the market recognizes the true uniqueness of that positioning.

It’s instructive to compare Tenet with Medtronic, which is often brought up in conversations about healthcare expansion. In order to propel recovery, Medtronic is placing a wager on device innovation and a lengthy pipeline. Tenet is currently producing operating leverage from companies that are already in operation. There is no truth to either story. However, they are distinct types of wagers.

Tenet Healthcare stock is no longer the neglected brand it was eighteen months ago, at $280 and change. The fact that the 52-week low is still at $157 serves as a reminder of how drastically sentiment has changed. Whether hospital demand remains stable, whether margin discipline persists, and whether a business that has garnered renewed attention can afford the price that attention now commands will determine whether that shift continues. It’s difficult not to be interested in what the upcoming quarters will show.